New antibiotic YK-1169 takes on deadly hospital pneumonia
Disease control
Not yet recruiting
This Phase 3 trial tests a new antibiotic called YK-1169 against a standard treatment (ceftazidime-avibactam) for adults with pneumonia caught in the hospital or from a ventilator. About 590 participants will receive either drug for 7-14 days. The main goal is to see if YK-1169 l…
Phase: PHASE3 • Sponsor: Nanjing Yoko Biomedical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC